ABBV
ABBVIE INC.
NYSE · usd
ABBVIE INC. (ABBV) trades at $288.84 (-2.05%) as of 7:59:14 PM EST on Nov 2, 2026, +9.90% over the past month. Market cap is $521.11B, with 2.7 days to cover in short interest.
Stock performance
How ABBVIE INC. (ABBV) stock has performed from one day to one year, with its 52-week range.
- 1D
- -2.05%
- 1W
- +0.73%
- 1M
- +9.90%
- YTD
- +26.41%
- 1Y
- +36.27%
- 52-wk range
- $190.75 – $298.74
Key statistics
Today's trading snapshot for ABBV: day range, open, previous close, volume and market cap.
- Day range
- $286.14 – $294.86
- Open
- $290.38
- Prev close
- $294.89
- Volume
- 8.85M
- Market cap
- $521.11B
- Shares out
- 1.77B
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for ABBVIE INC.: P/E, P/S, P/B, ROE and more.
- P/E
- 82.85
- P/S
- 8.09
- P/B
- -87.80
- P/FCF
- 28.62
- ROE
- -106.0%
- ROA
- 4.7%
- Debt/Equity
- -11.93
- Div yield
- 2.30%
As of Oct 30, 2026
8-K filings
Material corporate events ABBVIE INC. has disclosed to the SEC on Form 8-K.
- Quarterly earningsOct 30, 2026
On October 30, 2026, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2026.
- Director appointmentOct 15, 2026
On October 14, 2026, AbbVie Inc. ("AbbVie") expanded the size of its Board of Directors (the "Board") from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers has been appointed to the Public Policy and Sustainability Committee of AbbVie.
- Guidance issuance or updateOct 5, 2026
AbbVie's full-year 2026 adjusted diluted earnings per share guidance range, including the impact of third-quarter 2026 acquired IPR&D and milestones expense, is $13.76 - $13.96. AbbVie's third-quarter 2026 adjusted diluted earnings per share guidance range, including the impact of third-quarter 2026 acquired IPR&D and milestones expense, is $3.73 - $3.77.
- Acquisition completionSep 3, 2026
On September 3, 2026, AbbVie Inc. (the "Company") issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc.
- Debt issuanceAug 18, 2026
AbbVie completed its previously announced underwritten public offering of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028, $1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028, $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2030, $1,500,000,000 aggregate principal amount of its 4.875% senior notes due 2031, $1,250,000,000 aggregate principal amount of its 5.050% senior notes due 2033, $1,500,000,000 aggregate principal amount of its 5.300% senior notes due 2036, $1,000,000,000 aggregate principal amount of its 5.450% senior notes due 2038, $1,500,000,000 aggregate principal amount of its 6.000% senior notes due 2056 and $500,000,000 aggregate principal amount of its 6.100% senior notes due 2066.
Dividend history and stock splits
ABBVIE INC.'s recent dividend payments and stock splits.
Dividends
- $1.82ex-div Jan 15, 2027
- $1.73ex-div Oct 15, 2026
- $1.73ex-div Jul 15, 2026
- $1.73ex-div Apr 15, 2026
Splits
No recent splits.
ABBV short interest
How heavily ABBV is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 2.7
- Short interest
- 15.58M
- Avg volume
- 5.72M
As of · reported to FINRA twice monthly.
ABBV news
The latest news and headlines about ABBVIE INC. (ABBV).
- The Best Dividend Stocks to Buy With $5,000 in NovemberpositiveThe Motley Fool· Nov 2, 2026
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?positiveThe Motley Fool· Nov 2, 2026
- ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline ProgresspositiveZacks Investment Research· Nov 2, 2026
- Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's CombopositiveThe Motley Fool· Nov 2, 2026
- Better Dividend ETF: iShares HDV's High Yields vs. ProShares NOBL's Dividend GrowthpositiveThe Motley Fool· Oct 31, 2026
Frequently asked questions
What is the ABBVIE INC. (ABBV) stock price today?
ABBVIE INC. (ABBV) is trading at $288.84 (-2.05% on the day) as of 7:59:14 PM EST on Nov 2, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is ABBVIE INC.?
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.
What is the short interest in ABBV?
As of Oct 15, 2026, ABBV has 15.58M shares short and 2.7 days to cover.
Does ABBVIE INC. (ABBV) pay a dividend?
Yes. ABBVIE INC. (ABBV)'s most recent dividend was $1.82 per share, with an ex-dividend date of Jan 15, 2027. Full ABBV dividend history is available from the Massive API.
What exchange is ABBV listed on?
ABBVIE INC. (ABBV) trades on NYSE in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of ABBV with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ABBV analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.